IMMUNOLOGICAL, BIOCHEMICAL, AND MOLECULAR STUDIES ON EPITHELIAL OVARIAN CANCER

上皮性卵巢癌的免疫学、生物化学和分子研究

• 批准号: 6237133
• 负责人: KENNETH O LLOYD
• 金额: $ 15.34万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-02-01 至 1998-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6237133
• 关键词: antitumor antibody; binding proteins; biomarker; blood group antigens; carbohydrates; epithelium; exopeptidase; female; folate; human subject; immunocytochemistry; laboratory mouse; molecular oncology; monoclonal antibody; mucins; neoplasm /cancer immunology; neoplastic transformation; ovary neoplasms; protein sequence; protein structure function; tissue /cell culture; tumor antigens; women's health

The major goal of this Project are to identify antigens characteristics of epithelial ovarian cancer (EOC) using mouse monoclonal antibodies (mAbs) and to study some aspects of the biology of ovarian epithelium and its malignant transformation. The antigens detected by the mAbs will be characterized using biochemical and molecular approaches. An important aim will be to identify mAbs that are suitable for use in clinical trials involving EOC. Among mAbs to be studied are mAb MX35 (detecting a 95,000 glycoprotein), mAbs VK-5, 6, and 7 (detecting the MUC-1 mucin epitope), mAb MW 207 (detecting folate-binding protein) and mAb VK-8 (detecting a novel EOC antigen). This Project will also test chimeric and humanized versions of an anti-blood group Le antibody for their specificity and other parameters. Another goal will be to use various mAbs to detect markers related to the progression of normal ovarian epithelium to EOC and markers suitable for the classification of ovarian tumors. Three types of antigens will be examined: 1) blood group antigens, 2) ectopeptidases, and 3) mucins. Mucins will be studied in more detail using biochemical and molecular techniques in order to understand the role played by mucins in EOC. Also, novel methods for the analysis of the carbohydrate content of glycoproteins and mucins will be developed. The accomplishment of theses goals will provide new reagents for the diagnosis and therapy of EOC and will lead to an understanding of the antigenic changes associated with the malignant transformation of normal ovarian epithelium, tumor progression, and the biological behavior of ovarian tumors.

该项目的主要目标是确定抗原特征 用鼠源性单抗治疗卵巢上皮性癌 (单抗)，并研究卵巢上皮生物学的某些方面和 它的恶变。单抗检测到的抗原将是 用生化和分子方法来表征的。一个重要的 目标将是确定适合用于临床试验的单抗 涉及平等机会委员会。待研究的单抗中有单抗MX35(检测到95,000 糖蛋白)，单抗VK-5、6和7(检测MUC-1粘蛋白表位)， 单抗MW 207(检测叶酸结合蛋白)和单抗VK-8(检测 新的EOC抗原)。该项目还将测试嵌合体和人性化 抗Le血型抗体的不同版本的特异性和 其他参数。另一个目标是使用各种单抗来检测 与正常卵巢上皮向EOC进展相关的标志物 适用于卵巢肿瘤分类的标记物。三 将检查抗原的类型：1)血型抗原，2) 外肽酶和3)粘蛋白。将对粘蛋白进行更详细的研究 利用生化和分子技术来了解 粘蛋白在EoC中的作用。此外，新的方法也分析了 糖蛋白和粘蛋白的碳水化合物含量将得到开发。 这些目标的实现将为以下工作提供新的试剂 对卵巢癌的诊断和治疗，有助于提高对卵巢癌的认识 正常人癌变相关的抗原性变化 卵巢上皮、肿瘤进展和卵巢癌细胞的生物学行为 卵巢肿瘤。